press releases

December 15, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and… Read More

Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls No serious adverse events related to TTFields were reported December 12, 2016 04:00 PM Eastern… Read More

Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer December 12, 2016 04:00 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) presented data on Dec. 12, 2016, from its phase 2 pilot… Read More

Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers December 08, 2016 07:42 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today the agenda for the company’s research and development day for analysts and investors, which will… Read More

Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone EF-14 patients treated with Optune together with temozolomide experienced a 70 percent improvement in survival rate at four years compared to… Read More

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data No device-related serious adverse events have been reported to date November 17, 2016 07:30 AM Eastern Standard Time… Read More

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning author Dr. Siddhartha Mukherjee as the keynote speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology on… Read More

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3 pivotal trial in newly diagnosed GBM which confirms the superior progression free and overall survival seen in… Read More

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma November 03, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that United Healthcare will cover Optune… Read More